Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OGA | O60502 | 10/20 | 0.53 |
| ▸ | DRD2 | P14416 | 7/20 | 0.38 |
| ▸ | DRD1 | P21728 | 7/20 | 0.38 |
| ▸ | DRD5 | P21918 | 6/20 | 0.38 |
| ▸ | DRD3 | P35462 | 6/20 | 0.38 |
| ▸ | DRD4 | P21917 | 4/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21762216 | 1.00 | OGA (0.53) | OGADRD2DRD1DRD5DRD3 | |
| SCHEMBL21753251 | 1.00 | OGA (0.53) | OGADRD2DRD1DRD5DRD3 | |
| SCHEMBL26622373 | 0.87 | OGA (0.52) | OGAPIK3CAMTOR | |
| SCHEMBL21761983 | 0.87 | OGA (0.55) | OGAPIK3CAMTOR | |
| SCHEMBL21761961 | 0.87 | OGA (0.55) | OGAPIK3CAMTOR | |
| SCHEMBL21761965 | 0.87 | OGA (0.55) | OGAPIK3CAMTOR | |
| SCHEMBL26608080 | 0.87 | OGA (0.55) | OGAPIK3CAMTOR | |
| SCHEMBL21761922 | 0.86 | OGA (0.51) | OGAPIK3CAMTOR | |
| SCHEMBL21761865 | 0.86 | OGA (0.51) | OGAPIK3CAMTOR | |
| SCHEMBL21761864 | 0.86 | OGA (0.51) | OGAPIK3CAMTOR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | ASCENEURON SA (CH) | 2023-10-24 | — | — | US | disclosed |
| WO-2020039028-A1 | TETRAHYDRO-BENZOAZEPINE GLYCOSIDASE INHIBITORS | ASCENEURON S. A. (CH) | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11795165-B2 | Tetrahydro-benzoazepine glycosidase inhibitors | BACE1, BACE2, BCHE | OGA 380/4885DRD2 1589/4885DRD1 2004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.